




RealRate

PHARMACEUTICAL 2022

ChemoCentryx Inc.
Rank 227 of 466



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ChemoCentryx Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ChemoCentryx Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 39% points. The greatest weakness of ChemoCentryx Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 127%, being 49% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	269,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	63,017
Liabilities, Non-Current	51,743
Other Assets	124,206
Other Compr. Net Income	-597
Other Expenses	302
Other Liabilities	24,772
Other Net Income	-1,836
Other Revenues	32,224
Property and Equipment	32,269
Research and Development	82,990
Selling, General and Administrative Expense	78,851

Output Variable	Value in 1000 USD
Assets	425,652
Liabilities	139,532
Expenses	162,143
Revenues	32,224
Stockholders Equity	286,120
Net Income	-131,755
Comprehensive Net Income	-132,054
Economic Capital Ratio	127%